Skip to main content

AELINTX

Harnessing the power of protein aggregation

Aelin Therapeutics is founded by VIB and its partner universities KULeuven, VUB and UGent in 2017. Their final purpose is to create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology, branded Pept-insTM, harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein. The company received a 27M€ Series A financing to bring a first Pept-in product to the market.

aelintx
aelintx2
aelintx

Contact

Aelin Therapeutics
Els Beirnaert, CEO

Gaston Geenslaan 1
3001 Leuven

[T] +32 (0)16/85 27 00